ID: ALA3644516

Max Phase: Preclinical

Molecular Formula: C10H12N2O5

Molecular Weight: 240.22

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  Cc1cn2c(nc1=O)O[C@H]1C(O)[C@@H](CO)O[C@H]12

Standard InChI:  InChI=1S/C10H12N2O5/c1-4-2-12-9-7(6(14)5(3-13)16-9)17-10(12)11-8(4)15/h2,5-7,9,13-14H,3H2,1H3/t5-,6?,7+,9-/m1/s1

Standard InChI Key:  WLLOAUCNUMYOQI-AOXOCZDOSA-N

Associated Targets(Human)

Uridine phosphorylase 1 88 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 240.22Molecular Weight (Monoisotopic): 240.0746AlogP: -1.44#Rotatable Bonds: 1
Polar Surface Area: 93.81Molecular Species: NEUTRALHBA: 7HBD: 2
#RO5 Violations: 0HBA (Lipinski): 7HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 12.98CX Basic pKa: CX LogP: -0.87CX LogD: -0.87
Aromatic Rings: 1Heavy Atoms: 17QED Weighted: 0.62Np Likeness Score: 1.49

References

1.  (2014)  Methotrexate adjuvants to reduce toxicity and methods for using the same, 

Source

Source(1):